Discounted Cash Flow
Integra Lifesciences Holdings Corp.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $992.1m | $74.6m | $69.1m | 7.5% | $1.00 |
| 2017 | $1.2b (19.8%) | $64.7m (-13.2%) | $71.0m (2.8%) | 5.4% (-27.5%) | $0.84 (-16.0%) |
| 2018 | $1.5b (23.9%) | $60.8m (-6.1%) | $121.9m (71.7%) | 4.1% (-24.2%) | $0.73 (-13.1%) |
| 2019 | $1.5b (3.1%) | $50.2m (-17.4%) | $161.9m (32.8%) | 3.3% (-19.9%) | $0.59 (-19.2%) |
| 2020 | $1.4b (-9.6%) | $133.9m (166.7%) | $164.9m (1.9%) | 9.8% (195.0%) | $1.58 (167.8%) |
| 2021 | $1.5b (12.4%) | $169.1m (26.3%) | $264.4m (60.3%) | 11.0% (12.3%) | $2.00 (26.6%) |
| 2022 | $1.6b (1.0%) | $180.6m (6.8%) | $222.1m (-16.0%) | 11.6% (5.7%) | $2.18 (9.0%) |
| 2023 | $1.5b (-1.0%) | $67.7m (-62.5%) | $73.1m (-67.1%) | 4.4% (-62.1%) | $0.85 (-61.0%) |
| 2024 | $1.6b (4.5%) | $-6.9m (-110.3%) | $25.0m (-65.8%) | -0.4% (-109.8%) | $-0.09 (-110.6%) |
| 2025 | $1.6b (1.5%) | $-516.5m (-7337.7%) | $-31.1m (-224.4%) | -31.6% (-7225.3%) | $-6.74 (-7388.9%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.